Healthcare Industry News: Omeros
News Release - August 13, 2008
Omeros Appoints David A. Mann to its Board of DirectorsSEATTLE, Aug. 13 (HSMN NewsFeed) -- Omeros Corporation has announced the appointment of David A. Mann to the Company's Board of Directors. Mr. Mann also serves as Chairman of the Board's audit committee.
"Dave's years of executive management experience in finance and operations in the biotechnology sector are an invaluable asset to Omeros," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "He is an important addition to our Board, and I expect that he will play an integral role as we prepare for product commercialization."
"Dr. Demopulos and his team have done an excellent job in advancing their PharmacoSurgery platform, and I am pleased to be working with them," commented David Mann. "With a deep pipeline focused on inflammation and CNS, Omeros represents an exciting opportunity."
Mr. Mann brings with him over 20 years of executive management, finance and operations experience in the biotechnology industry. He was executive vice president and chief financial officer at Immunex prior to and during its acquisition by Amgen, and held senior financial positions at the Fred Hutchinson Cancer Research Center. Mr. Mann serves on the Board of Directors of Trubion Pharmaceuticals, and is on the advisory board of the Western Washington University College of Business and Economics and the Western Washington University Foundation Board. He is a former Certified Public Accountant, and earned his M.B.A. from the University of Washington and a B.A. from Western Washington University.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.Omeros.com.
Source: Omeros Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.